
Editor's Note: In breast cancer diagnosis and treatment, standardized care and quality control remain long-term priorities for ensuring consistent standards of care across China and benefiting more patients. As treatment options evolve rapidly and clinical concepts continue to advance, clinicians are increasingly focused not only on improving patient survival but also on quality of life and individual patient needs. Recently, the 2026 Conference on Standardized Breast Cancer Diagnosis, Treatment, and Quality Control was held in Beijing. Oncology Frontier invited Professor Qiao Li from the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, who co-chaired the conference, for an interview. Drawing on frontline clinical practice, she shared her perspectives on fertility preservation for young patients with breast cancer, updates to the Guidelines for Rational Drug Use in Breast Cancer, and other topics of major interest in the field.
01
Oncology Frontier:
As a co-chair of the conference, you participated in its preparation and agenda design. What were the academic highlights of this year’s meeting, and which sessions were of particular interest to you?
Professor Qiao Li: This conference was guided by Academician Binghe Xu and led by Professor Fei Ma, with a rich program of topics centered on standardized breast cancer diagnosis and treatment and quality control.
China’s breast cancer quality control initiative has now been underway for eight years. It covers numerous treatment centers across multiple provinces and continues to expand. The comprehensive report presented at the opening of this conference showed that the implementation of quality control measures has genuinely improved the standards of standardized breast cancer care across centers nationwide. Several clinical indicators have improved, benefiting more patients with breast cancer in multiple ways.
Beyond the central theme of quality control, the conference also incorporated several noteworthy topics. Fertility preservation for young patients with cancer was one particularly important focus, covering practical initiatives such as the establishment of fertility-friendly wards and fertility preservation programs. This direction is consistent with policy priorities from the State Council to the National Health Commission, and is also a key area of focus in China’s 15th Five-Year Plan. It responds to the country’s current demographic needs. Fertility preservation focuses on safeguarding reproductive potential among patients of childbearing age and young patients with cancer. By addressing patients’ reproductive wishes, it represents an important measure for improving their overall quality of life.
Fertility preservation involves multiple disciplines. Accordingly, this conference brought together reproductive specialists in gynecology, genetic counseling experts, statisticians, and oncology specialists from various disciplines. Through several sessions, including overall project presentations, discussions of implementation details, and clinical consultation and exchange, we hope to provide further support for fertility preservation initiatives for patients with cancer in the future.
02
Oncology Frontier:
At the conference, you introduced the fertility preservation initiative for young patients with breast cancer and the development of fertility-friendly wards. In your view, which challenges in the diagnosis and treatment of young patients with breast cancer should fertility-friendly wards prioritize addressing? As these initiatives move from proposals into routine clinical workflows, which aspects require multidisciplinary consensus?
Professor Qiao Li: Breast cancer predominantly affects women, and the proportion of women of childbearing age and young patients with breast cancer is increasing, as is the number of patients in these groups. Against this background, advancing fertility preservation programs and establishing fertility-friendly wards have considerable clinical and social significance.
Based on our daily clinical practice and our experience in developing fertility-friendly wards at our hospital, several challenges remain.
On the one hand, greater attention needs to be paid to patients’ reproductive needs during their initial consultations. When patients first seek medical attention, they are often more concerned about starting anticancer treatment promptly and hope to proceed with surgery, chemotherapy, and other treatments as soon as possible. If fertility-related counseling is not provided early in the treatment process, some patients may later have regrets. Many anticancer drugs can cause irreversible damage to ovarian function and fertility. Therefore, providing patients with information about fertility preservation and the opportunity to consider their options from the very beginning of diagnosis and treatment is a priority that fertility-friendly initiatives must address.
On the other hand, multidisciplinary collaboration and referral pathways need to be further strengthened. Patients are usually first seen by oncologists, whereas fertility preservation requires the involvement of reproductive specialists in gynecology and genetic counseling experts. Establishing referral channels between oncology, gynecology, and reproductive medicine departments, enabling rapid transfer of patient information and effective communication, and minimizing the time patients spend navigating the process are all key priorities for advancing fertility preservation.
In addition, external factors—including policies, medical insurance, public opinion, information dissemination channels, and the online environment—also need to give greater attention and support to fertility preservation, working together to advance these initiatives.
03
Oncology Frontier:
The launch ceremony for the third edition of the Guidelines for Rational Drug Use in Breast Cancer will be held at this conference. What issues do you think should receive particular attention in this update to ensure that the recommendations can be effectively implemented in clinical practice? From the perspective of clinicians using the guidelines, what do you hope to see in the third edition?
Professor Qiao Li: This conference has launched the update of the third edition of the Guidelines for Rational Drug Use in Breast Cancer. The update was initiated by the Chinese Pharmacists Association and brings together breast cancer experts from across China, covering multiple disciplines, including medical oncology, surgery, radiation oncology, diagnostic imaging, ultrasound diagnosis, pathology, and pharmacy. The pharmacy team will play an important role in this update, with numerous pharmacists participating in the guideline revision.
In recent years, many new anticancer drugs have emerged in the field of breast cancer, with advances in ADCs, immunotherapy, and small-molecule targeted therapies. Meanwhile, China’s domestic drug development capabilities have continued to improve, and reports on innovative drugs developed in China are becoming increasingly common at international academic conferences. As a national-level guide for medication use, these guidelines need to update their recommendations and standards for rational drug use accordingly and provide appropriate recommendations for the clinical application of innovative drugs.
In this guideline update, I am particularly interested in the standardized use of ADCs and small-molecule targeted agents. Several small-molecule targeted drugs have received approval for new indications this year and have been included in medical insurance coverage. As innovative drugs become accessible to more patients, standardized guidance on their use is essential. This should cover aspects such as administration, dosage, safety management, and dose adjustments, with recommendations developed through the joint efforts of multidisciplinary experts. We very much look forward to the official release of the updated guidelines in the near future.